Jade Biosciences Reports Positive Interim Results in Trial of IgA Nephropathy Drug; Shares Rise
MT Newswires Live
Jun 01
Jade Biosciences (JBIO) said Monday that interim phase 1 trial results showed its experimental immunoglobulin A nephropathy treatment, JADE101, delivered rapid, deep and sustained reductions in IgA levels in healthy volunteers.
The company said JADE101 achieved about 70% reductions in IgA levels that were sustained for 12 weeks at the 700 mg dose. The therapy was generally well tolerated across all tested dose levels, with no serious adverse events or study discontinuations reported, the company said.
Jade said the data suggest JADE101 could potentially be administered once every 12 weeks, supporting a more convenient dosing schedule than existing therapies.
Shares of Jade Biosciences were 9.8% higher in premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.